Clinical Trial: The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms: A Double-Blind Placebo-Controlled Clinical Trial and Analysis of Inflammatory Markers and Microbiome

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07711444) titled 'The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms: A Double-Blind Placebo-Controlled Clinical Trial and Analysis of Inflammatory Markers and Microbiome' on July 14.

Brief Summary: We conducted a 12-week, double-blind, randomized, placebo-controlled trial to assess the effectiveness of EPA or SPM treatments versus a placebo in managing Long COVID symptoms in adult patients. We planned to enroll 240 eligible participants from various general and psychiatric hospitals in Taiwan. The focus was on evaluating the therapeutic ...